[HTML][HTML] Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy

Y Chen, S Shi, Y Dai - Biomedicine & Pharmacotherapy, 2022 - Elsevier
Doxorubicin (DOX), as a kind of chemotherapy agent with remarkable therapeutic effect, can
be used to treat diverse malignant tumors clinically. Dose-dependent cardiotoxicity is the …

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling

NH Mustafa, J Jalil, S Zainalabidin… - Frontiers in …, 2022 - frontiersin.org
Cardiovascular diseases have become a major clinical burden globally. Heart failure is one
of the diseases that commonly emanates from progressive uncontrolled hypertension. This …

Neprilysin inhibition in the prevention of anthracycline-induced cardiotoxicity

AM Sobiborowicz-Sadowska, K Kamińska… - Cancers, 2023 - mdpi.com
Simple Summary Anthracycline-induced cardiotoxicity (AIC) poses a significant clinical
challenge in the management of cancer patients. Thus, the development of effective …

Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK/SIRT-1/PGC-1α-mediated mitochondrial biogenesis

M Chen - Toxicology Research, 2023 - academic.oup.com
We aimed to probe the functions and possible mechanisms of empagliflozin in doxorubicin
(Dox)-caused cardiotoxicity. First, a cardiotoxicity rat model was built by continuously …

Sacubitril/valsartan alleviates sepsis-induced myocardial injury in rats via dual angiotensin receptor-neprilysin inhibition and modulation of inflammasome/caspase 1 …

MMM Refaie, M El-Hussieny, AMA Bayoumi… - European Journal of …, 2024 - Elsevier
Sepsis is a life-threatening situation that ultimately affects cardiac function, leading to
cardiomyopathy and myocardial injury as a result of uncontrolled response to infection. Till …

[HTML][HTML] Dapagliflozin may protect against doxorubicin-induced cardiotoxicity

S Ulusan, K Gülle, A Peynirci, M Sevimli… - Anatolian journal of …, 2023 - ncbi.nlm.nih.gov
Background: Doxorubicin is a widely used agent in the treatment of cancer, but the
cardiotoxicity associated with this drug limits its potential for use. The cardioprotective effects …

Empagliflozin and sacubitril/valsartan reverse methotrexate cardiotoxicity by repressing oxidative stress and hypoxia in heart embryonic H9c2 cardiomyocytes-the role …

Z Doğan, DD Ergun, S Durmus, H Şahin, GE Şentürk… - 2023 - acikerisim.atlas.edu.tr
Objective: Oxidative stress and hypoxia play an important role in the pathogenesis of various
cardiovascular diseases. We aimed to evaluate the effectiveness of sacubitril/valsartan (S/V) …

Inflammatory markers S100A8/A9 and metabolic alteration for evaluating signs of early phase toxicity of anticancer agent treatment

T Morikawa-Ichinose, Y Fujimura, M Kumazoe… - Food and Chemical …, 2022 - Elsevier
Anticancer agents can cause various side effects, including tissue damages/inflammatory
reactions. Drug-responsive biomarkers are essential for evaluating drug toxicity in disease …

[HTML][HTML] GSK2795039 prevents RIP1-RIP3-MLKL-mediated cardiomyocyte necroptosis in doxorubicin-induced heart failure through inhibition of NADPH oxidase …

XJ Zhang, L Li, AL Wang, HX Guo, HP Zhao… - Toxicology and Applied …, 2023 - Elsevier
Doxorubicin (DOX), which is widely used for the treatment of cancer, induces
cardiomyopathy associated with NADPH oxidase-derived reactive oxygen species …

Sacubitril/valsartan cardioprotective effect against cisplatin-induced cardiotoxicity via modulation of VEGF/eNOS and TLR4/TNFα/IL6 signalling pathways

MM Mahmoud Refaie, R Ahmed Rifaai… - Journal of Pharmacy …, 2023 - academic.oup.com
Objectives Drug-induced cardiac injury is a potentially preventable cause of heart failure.
Cisplatin (CIS) is a widely used chemotherapeutic agent complicated with cardiotoxicity that …